AlphaFold predicted structure
PGAP2 · Q9UHJ9

Mean pLDDT
90.1/ 100
Very high
254 residues
Confidence breakdown
- Very high(≥ 90)72%
- Confident(70–90)19%
- Low(50–70)6%
- Very low(< 50)3%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
post-GPI attachment to proteins 2
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
Congenital disorders of glycosylation
BIALLELIC, autosomal or pseudoautosomalDDG2P
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalChildhood onset dystonia, chorea or related movement disorder
Clefting
Unknownhyperphosphatasia-intellectual disability syndrome
Intellectual disability
hereditary disease
genetic developmental and epileptic encephalopathy
Dysequilibrium syndrome
familial hemolytic anemia
omphalocele
Micrognathia
Hypoplasia of the corpus callosum
amelogenesis imperfecta
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Acyltransferase PGAP2
Involved in the fatty acid remodeling steps of GPI-anchor maturation where the unsaturated acyl chain at sn-2 of inositol phosphate is replaced by a saturated stearoyl chain. May catalyze the second step of the fatty acid remodeling, by reacylating a lyso-GPI intermediate at sn-2 of inositol phosphate by a saturated chain (By similarity). The fatty acid remodeling steps is critical for the integration of GPI-APs into lipid rafts (PubMed:23561846)
PGAP2 · Q9UHJ9

Mean pLDDT
90.1/ 100
Very high
254 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0